

**SPECIALISED COMMISSIONING - CLINICAL EVIDENCE EVALUATION
CRITERIA FOR A CLINICAL COMMISSIONING POLICY PROPOSITION THAT IS
NOT PROGRESSING**

URN: 1817

TITLE: Infliximab for refractory neurosarcoidosis

CRG: Neurosciences

NPOC: Trauma

Date: 20/02/19

Advice	Conclusion of the panel
<p>The Panel should provide advice on matters relating to the evidence base and policy development and prioritisation. Advice may cover:</p> <ul style="list-style-type: none"> • Uncertainty in the evidence base • Challenges in the clinical interpretation and applicability of policy in clinical practice • Challenges in ensuring policy is applied appropriately • Issues with regard to value for money • Likely changes in the pathway of care and therapeutic advances that may result in the need for policy review. 	<p>Clinical Panel were uncertain over the level of evidence and extent of evidence base provided. The PWG are asked to review the evidence again and consider submitting a policy proposition to Clinical Panel as a routine commissioning position, so this can be considered again at a future meeting. There should be sufficient pharmacy involvement to ensure that the appropriate dose is selected from the evidence base and information used from other clinical areas to identify potential side effects. In addition, the PWG should ensure that there is:</p> <ul style="list-style-type: none"> • Clarity in patient pathway. • Detailed stopping and starting criteria. • Detailed information on management of relapse. • Information on registry data collection. • Consideration of the use of biosimilars.

Report approved by:
James Palmer
Clinical Panel Chair
22/2/19